Samus Therapeutics
Boston
Massachusetts
United States
Website: http://samustherapeutics.com/
Email: info@samustherapeutics.com
About Samus Therapeutics
Samus Therapeutics is a privately held Boston-based biopharmaceutical company developing novel therapeutics targeting the epichaperome, a foundational protein complex emergent from multiple disease states, including cancer and neurological diseases, such as Alzheimer's, Parkinson's and chronic traumatic encephalopathy. Samus was founded by Drs. Gabriela Chiosis and Larry Norton on research conducted at the Chiosis Laboratory at the Memorial Sloan Kettering Cancer Center, and at Rockefeller University and Weill Cornell Medicine, and is led by Jonathan Lewis, MD, PhD, its Chief Executive Officer. The Company's lead oncology program, epichaperome inhibitor PU-H71, is advancing into Phase 1b or 1b/2 clinical studies in pancreatic cancer, breast cancer, myeloproliferative neoplasms and lymphoma/leukemia. The Company's lead CNS therapeutic, PU-AD, is being studied in Alzheimer's and CTE disease models. In parallel with its therapeutics program, Samus is advancing companion diagnostics PU-PET and PU-CYT.LEADERSHIP:
Founders: Gabriela Chiosis and Larry Norton
CEO: Jonathan Lewis
CMO: James Armitage
CFO: Dick Bagley
CRO: Bob Morgan
CSO: Barbara Wallner
13 articles about Samus Therapeutics
-
Samus Therapeutics Announces First Patient Dosed in Phase 1b Study of Icapamespib in Recurrent Malignant Glioma
1/5/2022
Samus Therapeutics, Inc. ("Samus Therapeutics" or the "Company"), today announced the first patient was dosed in the multicenter Phase 1b study of icapamespib in patients with recurrent malignant glioma.
-
Samus Therapeutics Announces Study Publication in Communications Biology on the Importance of Epichaperome Inhibition for Enhancing the Vulnerability of Cancer Cells
12/1/2021
Samus Therapeutics, Inc. ("Samus Therapeutics" or the "Company"), today announced the publication on November 25, 2021 of an open article in Communications Biology about how epichaperome inhibition by zelavespib (PU-H71) can increase the vulnerability of cancer cells to traditionally poor performing therapeutics.
-
Samus Therapeutics Announces Publication of Study on Epichaperome Chemical Probes in Nature Communications
9/2/2021
Samus Therapeutics, Inc., a privately held, Boston-based biopharmaceutical company developing epichaperome inhibitors to treat central nervous system diseases and hematologic malignancies, announced the publication of an open article in Nature Communications.
-
Samus Therapeutics Receives IND Clearance from FDA for PU-AD for the Treatment of Recurrent Malignant Glioma
5/11/2021
Samus Therapeutics, Inc., a privately held, Boston-based biopharmaceutical company developing epichaperome inhibitors to treat CNS diseases and hematologic malignancies, announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application to develop PU-AD for the treatment of recurrent malignant glioma.
-
Clearance of the IND allows Samus to proceed with a Phase Ib trial to assess the safety, tolerability and pharmacokinetics of PU-AD in a small group of patients with recurrent malignant glioma.
-
Samus Therapeutics Presents Phase 1 PU-AD Study Results at AAIC 2020 Advancing the Company's Platform for Treating Neurodegenerative Diseases
7/29/2020
Samus Therapeutics, Inc., a privately held, biopharmaceutical company developing small molecule epichaperome inhibitors, announced the presentation of safety and pharmacokinetic data from the Company's recently completed PU-AD healthy volunteer Phase 1 study at the Alzheimer's Association International Conference.
-
Study Published in Nature Communications Highlights the Role of the Epichaperome in Protein Connectivity-based Dysfunction in Alzheimer's Disease
2/4/2020
Samus Therapeutics, Inc. ("Samus" or the "Company"), a privately held, Boston-based, biopharmaceutical company developing epichaperome inhibitors to intervene in pathological processes and initiate the degradation of disease-associated proteins, today announced the publication of preclinical research in the journal Nature Communications.
-
Samus Therapeutics to Present at BIO CEO & Investor Conference
2/4/2020
Samus Therapeutics, Inc. ("Samus" or the "Company"), a privately held, Boston -based, biopharmaceutical company developing epichaperome inhibitors to intervene in pathological processes and initiate the degradation of disease-associated proteins, today announced that Dick Bagley , President and Interim Chief Executive Officer,
-
Samus Therapeutics Announces Presentation of Phase 1b Study Evaluating Orally Administered PU-H71 with Ruxolitinib in Myelofibrosis at the ASH 2019 Annual Meeting
12/9/2019
Samus Therapeutics, Inc. ("Samus" or the "Company"), today announced a poster presentation addressing the Company's Phase 1 study evaluating orally administered PU-H71 with ruxolitinib in patients with myelofibrosis no longer fully responsive to orally administered ruxolitinib.
-
50 million people worldwide live with symptomatic Alzheimer's, which has no cure. In honor of September 21st being World Alzheimer's Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.
-
Samus Therapeutics Launches PU-AD Clinical Program in Alzheimer's Disease
7/23/2019
IND Cleared and First Phase 1 Study Subject Dosed
-
Samus Therapeutics Announces PU-H71 Granted Orphan Drug Designation and First Patient Dosed in Phase 1b Study in Myelofibrosis
6/13/2018
The Company also announced today that it has dosed the first patient in a Phase 1b dose-escalation study of PU-H71 in patients with myelofibrosis.
-
Samus Therapeutics Announces Launch Of Expanded Clinical Development Programs For Novel Anti-Epichaperome Small Molecules To Diagnose And Treat Cancer And Neurodegenerative Disease
3/30/2017